The therapeutic community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s demonstrating significant potential in clinical trials for addressing obesity. Unlike some current weight loss solutions, retatrutide appears to deliver a more substantial loss in body mass and improve metabolic function, part